Home
Scholarly Works
Evaluation of the safety of continuing trastuzumab...
Conference

Evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.

Authors

Barron C; Kaur U; Mustafa Al-Hussein M; Brown M; Cosman T; Mukherjee S; Ellis PM; Dhesy-Thind SK; Leong D

Volume

36

Pagination

pp. e18548-e18548

Publisher

American Society of Clinical Oncology (ASCO)

Publication Date

May 20, 2018

DOI

10.1200/jco.2018.36.15_suppl.e18548

Conference proceedings

Journal of Clinical Oncology

Issue

15_suppl

ISSN

0732-183X
View published work (Non-McMaster Users)

Contact the Experts team